A Review of Eslicarbazepine Acetate for the Adjunctive Treatment of Partial-Onset Epilepsy

Journal of Central Nervous System Disease

Review

Rajinder P. Singh¹  Jorge J. Asconapé¹ 

[1] Department of Neurology, Stritch School of Medicine, Loyola University Medical Center, Maywood, Illinois 60153, USA.;

关键词: eslicarbazepine;    licarbazepine;    dibenzazepine;    voltage-gated sodium channel;    partial-onset seizures;    epilepsy;   

DOI  :  10.4137/JCNSD.S4888

来源: Sage Journals

【 摘 要 】

Eslicarbazepine acetate (ESL) is a novel antiepileptic drug indicated for the treatment of partial-onset seizures. Structurally, it belongs to the dibenzazepine family and is closely related to carbamazepine and oxcarbazepine. Its main mechanism of action is by blocking the voltage-gated sodium channel. ESL is a pro-drug that is rapidly metabolized almost exclusively into S-licarbazepine, the biologically active drug. It has a favorable pharmacokinetic and drug-drug interaction profile. However, it may induce the metabolism of oral contraceptives and should be used with caution in females of child-bearing age. In the pre-marketing placebo-controlled clinical trials ESL has proven effective as adjunctive therapy in adult patients with refractory of partial-onset seizures. Best results were observed on a single daily dose between 800 and 1200 mg. In general, ESL was well tolerated, with most common dose-related side effects including dizziness, somnolence, headache, nausea and vomiting. Hyponatremia has been observed (0.6%-1.3%), but the incidence appears to be lower than with the use of oxcarbazepine. There is very limited information on the use of ESL in children or as monotherapy.

【 授权许可】

CC BY-NC   
© 2011 SAGE Publications.

【 图 表 】

Figure 4.

Figure 1

Figure 1.

Figure 3.